Search PubMed⌕ Search

Biomedical subjects

H Suematsu

Publications and source records attributed to H Suematsu.

At least 55 records · Page 3Linked to original sources
PubMed1986

Anorexia nervosa in monozygotic twins.

Which is more important, hereditary factors or psychological environment factors, in the etiology of anorexia nervosa? The question is studied by considering 7 cases of anorexia nervosa in monozygotic twins of the authors' own practice. In 5 of 7 cases, only 1 of a set of twins was found to be suffering from anorexia nervosa. On the other hand, in 2 of 7 cases, both twins were diagnosed as having anorexia nervosa. Even in the concordant cases studied by the authors, however, the quality or degree of anorexia nervosa in each case was different. Therefore, even given the existence of concordant cases, without inquiring precisely into the quality or degree of anorexia nervosa, it is not possible to conclude that hereditary factors play a determining role in the etiology of anorexia nervosa.

Adolescent↗
PubMed1985

Statistical studies on anorexia nervosa in Japan: detailed clinical data on 1,011 patients.

Statistical studies on anorexia nervosa in Japan were carried out by our research group. Questionnaires were sent to physicians at 1,030 representative institutions throughout Japan and data were collected from 315 institutions. The total number of patients with anorexia nervosa in 1981 was 940 outpatients and 372 inpatients. The number of patients in 1981 was twice as high as in 1976. Detailed data on 1,011 patients were investigated. As most of the patients had certain endocrinological abnormalities which improved after weight gain, indications are that at least a part of the endocrinological abnormalities might be secondary changes due to weight loss.

Adolescent↗
PubMed1985

Statistical studies on the prognosis of anorexia nervosa.

Statistical studies on the prognosis of anorexia nervosa were carried out by our research group. Subjects were 224 cases from 36 university hospitals throughout Japan. A questionnaire was mailed to each of the 224 patients in cooperation with their doctors. The outcome of 143 of the 224 cases was judged by their doctors as 'good' in 47 cases, 'intermediate' in 69 cases and 'poor' in 19 cases. 8 of the patients had died. The prognosis of typical cases was much poorer than that of atypical cases.

Adolescent↗
PubMed1984

[Mitral valve prolapse in patients with anorexia nervosa].

Mitral valve prolapse (MVP) is frequently observed in patients with low body weight and/or skeletal abnormalities such as pectus excavatum and straight spines. There may be a variety of associated autonomic dysfunctions. Whether MVP is a complication of anorexia nervosa which has similar clinical features, including weight loss, skeletal abnormalities and autonomic dysfunctions, has not been reported. The present study was an investigation of the incidence of MVP and cardiac function in anorexia nervosa by echocardiography. Two-dimensional and M-mode echocardiography, and systolic time intervals were evaluated for 19 women with anorexia nervosa, from 13 to 25 years of age and having a mean age of 18.2 years. Their body weights ranged from 23.9 to 43 kg with a mean of 33.5 kg, and were at least 25% less than their ideal body weights (ranges were from 25 to 52%). The same studies were performed for 19 women with MVP diagnosed echocardiographically and without anorexia nervosa as controls. Their ages ranged from 14 to 26 years. Results were as follows: MVP was observed in 74% of patients with anorexia nervosa. The mean heart rates were 51.7 and 70.5/min in the anorexia nervosa and control groups, respectively. A significant difference (p less than 0.001) was observed between the two groups. The mean heart rate of patients with anorexia nervosa having MVP of both leaflets and no MVP were 45.8 and 59.0/min, respectively. The difference between these two sub-groups was statistically significant (p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗
PubMed1980

Thionamide therapy in Graves' disease: relation of relapse rate to duration of therapy.

The present study was undertaken to investigate whether there is a rational basis for the usual long periods of thionamide therapy in patients with hyperthyroid Graves' disease. Eighty untreated patients were given the minimum dose of thionamide drug needed to maintain serum thyroxine, triiodothyronine, and thyrotropin (TSH) concentrations within their normal ranges. Thyrotropin-releasing hormone (TRH) tests were done at 6 monthly intervals for 2 years. Among patients who had positive responses of TSH to TRH, approximately 10 patients every 6 months were asked to stop thionamide therapy and were followed up for at least 1 year after discontinuation of drugs. In the groups treated for 6, 12, 18, and 24 months, relapses occurred in nine of 13, five of nine, three of 12, and two of 11 patients, respectively. Values for thyroid function tests before and at the end of treatment were not different among these four groups of patients. The overall remission rates were not ascertained. However, a minimum of 1 year's treatment is recommended, at least in Japan.

Adolescent↗
PubMed1979

Plasma dopamine-beta-hydroxylase activity and thyroid suppressibility in Graves' disease.

Plasma dopamine-beta-hydroxylase (DBH) activity, serum T4, T3, T3U, and the 24-hr thyroid uptake before triiodothyronine suppression testing were studied in 34 patients with treated Graves' disease. Although all of them were in the euthyroid state, there was a statistically significant difference in presuppression plasma DBH activity between those patients who showed suppression of their RAI uptake with triidothyronine and those who did not. This suggests a relationship between plasma DBH activity and thyroid suppressibility.

Dopamine beta-Hydroxylase↗
PubMed1978

[Changes in serum thyrotropin, thyroxine and triiodothyronine after complete thyroidectomy (author's transl)].

Changes in serum TSH, T4 and T3 concentrations after complete thyroidectomy were observed for 4 weeks in 9 euthyroid patients with thyroid carcinoma. Completeness of the thyroidectomy was confirmed by a 131 I scintigram performed one or two months after the operation. Serum TSH levels rose progressively during the 4 weeks of observation, and a significant increase was noticed as early as 3 days after the thyroidectomy. Serum T4 and T3 concentrations decreased significantly 3 days and 18 hrs, respectively, after the thyroidectomy. A sharp decrease in serum T3 concentrations within 18 hrs without a significant change in serum T4 levels and possibly without a significant change in the amount of T3 derived from T4 suggests that the amount of T3 secreted from the thyroid is large enough to affect serum T3 concentrations. The rate of decrease of serum T4 (t 1/2: 16 days) or serum T3 (t 1/2: 23 days) after the 3rd day of the thyroidectomy was much slower than the rate of disappearance of labeled T4 or T3 reported previously. The slow decrease rate of serum T3 is probably due to the conversion of T4 to T3 in peripheral tissues, and that of serum T4 may be due to either the decrease in T4 disposal rate in hypothyroidism or due to the release of T4 from peripheral tissues to serum.

Adult↗
PubMed1978

Responses to TRH and T3 suppression tests in euthyroid subjects with a family history of Graves' disease.

The relationship of Graves' disease and heredity was studied in 97 clinically and biochemically euthyroid relatives (resin T3 uptake and serum T3, T4, and TSH within normal ranges) who had more than two thyrotoxic relatives within the second degree relationship. TRH tests were preformed in all 97 cases. In 56 of the 97, T3 suppression tests were performed shortly after the TRH test. Results revealed that 29 of the 97 (29.9%) showed an abnormal response to TRH. fourteen of these (14.4%) revealed no response or a hyporesponse, and 15 (15.5%) revealed a hyperresponse to TRH. Four of 56 (7.1%) were T3 nonsuppressible. Seven individuals who showed no response or a hyporesponse to TRH consisted of 2 nonsuppressible and 5 suppressible subjects. In 14 non- or hyporesponsive cases, serum T3 (1.51 +/- 0.05 ng/ml; mean +/- SE) and T4 (9.91 +/- 0.31 micrograms/dl) were significantly higher compared with those of normal responders (1.30 +/- 0.04 ng/ml, 8.57 +/- 0.21 micrograms/dl; P less than 0.001) or hyperresponders (1.16 +/- 0.06 ng/ml, 7.77 +/- 0.63 micrograms/dl; P less than 0.01). There was no correlation between TRH responsiveness and T3 suppressibility. A relatively high occurrence of thyroglobulin and microsomal antibodies was observed, further suggesting a hereditary predisposition. The findings indicate that even in euthyroid relatives with a family history of Graves' disease who have no clinical or biochemical abnormalities of thyroid dysfunction, many have abnormalities in TRH responsiveness, T3 suppressibility, and thyroidal antibodies.

Adolescent↗
PubMed1976

[TRH and T3 suppression tests after 131I therapy of thyrotoxicosis (author's transl)].

TRH and T3 suppression tests were performed on patients (124 cases) with Graves' disease who underwent radiation therapy. TRH test was performed at 4-6 months (Group I), 6-12 months (Group II), 12-24 months (Group III) and 24-50 months (Group IV) after final radiation therapy, and T3 suppression test was performed just after each TRH test. The response to TRH test was defined as positive when the basal TSH value was less than 2.0 muU/ml and the peak value was more than 6.2 muU/ml following TRH (500 mug) injection. T3 suppression test was performed by measuring the 24-hr thyroidal uptake of radioiodine after daily administration of 75 mug of T3 for 8 days. The response was defined as positive when the value for 24-hr uptake after T3 administration was less than half of the control value. The results were as follows; 1) Among 124 patients in Group I to IV who were clinically euthyroid and whose T3-RU and T4 values were normal, compared with other groups, Group IV (2-4.2Y) showed a significantly higher percentage of positive responses to both TRH and T3 suppression tests. However, among 49 of 124 patients whose T3 was also normal, there were no significant differences between the groups. 2) The value of triiodothyronine was above the normal range in many cases up to 2 years after radiation therapy (in Group I, II, III). 3) There were no significant differences in the percentage of hyperresponses between any of the four groups. Half of the patients who showed positive responses to TRH test showed exaggerated responses. 4) In all cases when the responses to TRH and T3 suppression tests changed from negative to positive, thyroxine and triiodothyronine concentrations must be within the normal range. In particular, the major determinant seems to be the value of triiodothyronine. 5) As in more than 30% of cases TRH and T3 supression tests changed from negative to positive, thyroxine and triiodothyronine concentrations must be within the normal range. In particular, the major determinant seems to be the value of triiodothyronine. 5) As in more than 30% of cases TRH and T3 suppression tests remained negative even though their T3-RU, T4, T3, values became normal after radiation therapy, the regulation of hypothalamo-hypophyseal thyroid axis do not always return to normal even though circulating thyroidal hormone level return to an euthyroid state.

Adult↗
PubMed1975

[Changes in responsivity to TRH test and T3-suppression test after surgical treatment of hyperthyroidism (author's transl)].

TRH test and T3 suppression test were performed on patients with Graves' disease who underwent subtotal thyroidectomy after treatment with antithyroid drugs for 2.5 approximately 5 months. On 43 or the patients, TRH test was performed before, 1 week after and 1 approximately 2 months after surgery and T3 suppression test was also performed in 1 approximately 2 months post-operative period. For other 3 groups of the patients TRH test was performed at 2 approximatley 6 months, 6 approximately 12 months, 12 approximately 24 months and 24 approximately 41 months after surgery, and T3 suppression test was also performed just after each TRH test. As to TRH test, the response was defined as positive when basal TSH value was less than 2.0 muU/ml and peak value was more than 6.2 muU/ml or the difference between basal TSH and peak TSH value was over 5 muU/ml following TRH (500 mug) injection. T3 suppression test was perfomed by measuring the 24-hr thyroidal uptake of radioiodine after daily administration of 75 mug of T3 for 8 days. The response was defined as positive when the value for 24-hr uptake after T3 administration was less than half of the control value. The results were as follows; (1) In 11 of 43 patients, response to TRH test already changed to positive 1 week after operation and in 21 of 43 patients TRH test changes to positive 1 approximately 2 months after operation. (2) In general, response to TRH test changed to positive earlier than response to T3 suppression test. (3) T3 suppression test in 1 approximately 2 months after operation was useful to evaluate prognosis. (4) A half of the positive respondents to TRH test showed exaggerated response. (5) Basal TSH value of positive respondents to TRH test was 9.27 +/- 1.81 muU/ml (mean +/- SE) which exceeded the normal range. (6) Some patients showed negative response to conventional T3 suppression test despite of their high basal TSH value. This might be due to the insufficient dose of T3 to suppress TSH. (7) Concerning patients whose serum T3-RU, T4, T3 and TSH were within normal limit after subtotal thyroidectomy, 80% of them showed correspondance in the results of TRH test and T3 suppression test.

Adolescent↗